Preferential attack on cancer by selected SH inhibitors.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents; D001201:Ascites / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009360:Neoplastic Cells, Circulating / Q000188:drug therapy / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000037:antagonists & inhibitors*; D014594:Uterine Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D013438:Sulfhydryl Compounds; D008466:Mechlorethamine; D005472:Fluorouracil